Apollo AyurVAID Launches India’s First ‘Tested Safe’ Ayurveda Products
Mumbai: Apollo AyurVAID, India’s leading NABH-accredited precision Ayurveda hospital network, has announced its strategic foray into the Ayurveda product segment, marking a significant expansion beyond clinical care. The company has launched 50 SKUs across classical Ayurveda formulations, OTC products, and medical foods, targeting a nationwide reach and ₹500 crores in products revenue in the next 5 years.
Apollo AyurVAID’s product range features clinically proven formulations certified safe by NABL-accredited laboratories for presence of heavy metals, aflatoxins, and microbial content. This industry-first safety benchmark sets a new standard for the Ayurveda product market, with consumers able to verify test results via QR code on packaging.
The portfolio includes classical formulations available through prescription and OTC products available through retail and digital platforms, featuring innovative formats like creams and transdermal pads. Apollo AyurVAID has partnered with Avesthagen Limited to co-develop scientifically validated, botanical-actives based dietary supplements, branded as ‘AvestaAyurVAID’.
Dr. Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals and Chairperson, Apollo AyurVAID, said, “Apollo AyurVAID’s foray into tested-safe Ayurveda products marks a pivotal step in redefining standards of safety, transparency, and efficacy in traditional medicine.”
Rajiv Vasudevan, Founder, MD, and CEO, Apollo AyurVAID, added, “We are extending our understanding of precision Ayurveda and credibility into a high-potential consumer space, with a vision to mainstream evidence-based Ayurveda services and products globally.”
Distribution Strategy
The products will be available across Apollo AyurVAID’s hospitals and clinics, the company’s website, Apollo Pharmacies, Apollo 24|7, and leading e-commerce platforms. This integrated channel approach aims to enable access and reach to a wider audience.
Nationwide Expansion
Apollo AyurVAID aims to expand its hospital network, scaling bed capacity to 350 and treating over 50,000 patients, with a revenue aspiration of ₹500 crores in the next 5 years. The company is committed to building a credible, science-led ecosystem for precision Ayurveda and evolving into a full-spectrum Ayurveda company.
